loading
Contineum Therapeutics Inc stock is traded at $13.45, with a volume of 4,977. It is down -1.47% in the last 24 hours and down -16.30% over the past month. Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
See More
Previous Close:
$13.65
Open:
$13.77
24h Volume:
4,977
Relative Volume:
0.07
Market Cap:
$333.56M
Revenue:
-
Net Income/Loss:
$-31.45M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-33.15M
1W Performance:
-25.90%
1M Performance:
-16.30%
6M Performance:
-15.94%
1Y Performance:
+0.00%
1-Day Range:
Value
$13.66
$14.21
1-Week Range:
Value
$12.33
$18.19
52-Week Range:
Value
$12.33
$22.00

Contineum Therapeutics Inc Stock (CTNM) Company Profile

Name
Name
Contineum Therapeutics Inc
Name
Phone
(858) 333-5280
Name
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
CTNM's Discussions on Twitter

Compare CTNM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
CTNM 13.70 333.56M 0 -31.45M -33.15M 0.00
VRTX 448.13 115.74B 10.63B -479.80M -1.35B 13.33
REGN 742.12 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 590.43 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.32 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.27 24.49B 3.30B -501.07M 1.03B 11.54

Contineum Therapeutics Inc Stock (CTNM) Latest News

pulisher
Nov 20, 2024

Contineum Therapeutics chief scientific officer sells $101,420 in stock - Investing.com

Nov 20, 2024
pulisher
Nov 18, 2024

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain - BioSpace

Nov 18, 2024
pulisher
Nov 18, 2024

Contineum Therapeutics Secures FDA Authorization for Novel Pain Treatment PIPE-791 | CTNM Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 17, 2024

(CTNM) Trading Signals - Stock Traders Daily

Nov 17, 2024
pulisher
Nov 14, 2024

75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve

Nov 14, 2024
pulisher
Nov 14, 2024

Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

Contineum Therapeutics to Attend Upcoming Investor Conferences - BioSpace

Nov 14, 2024
pulisher
Nov 13, 2024

Contineum Therapeutics Announces Financial Results for the Quarter Ended September 30, 2024 - Defense World

Nov 13, 2024
pulisher
Nov 12, 2024

Contineum Therapeutics' SWOT analysis: promising pipeline drives stock outlook - Investing.com India

Nov 12, 2024
pulisher
Nov 09, 2024

Contineum Therapeutics (NASDAQ:CTNM) Releases Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat

Nov 09, 2024
pulisher
Nov 07, 2024

Royal Bank of Canada Lowers Contineum Therapeutics (NASDAQ:CTNM) Price Target to $31.00 - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Ionis to present at upcoming investor conferences - Quantisnow

Nov 07, 2024
pulisher
Nov 07, 2024

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - BioSpace

Nov 07, 2024
pulisher
Nov 06, 2024

Contineum (CTNM) Reports Strong Trial Progress, $214M Cash Runway Through 2027 | CTNM Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 06, 2024

Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow

Nov 06, 2024
pulisher
Nov 06, 2024

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - Quantisnow

Nov 06, 2024
pulisher
Nov 04, 2024

Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE - Quantisnow

Nov 04, 2024
pulisher
Oct 27, 2024

(CTNM) Proactive Strategies - Stock Traders Daily

Oct 27, 2024
pulisher
Oct 24, 2024

Contineum Therapeutics (NASDAQ:CTNM) Stock Rating Upgraded by Baird R W - Defense World

Oct 24, 2024
pulisher
Oct 23, 2024

Contineum Therapeutics (NASDAQ:CTNM) Upgraded at Baird R W - MarketBeat

Oct 23, 2024
pulisher
Oct 23, 2024

Ionis to hold third quarter 2024 financial results webcast - Quantisnow

Oct 23, 2024
pulisher
Oct 23, 2024

Baird bullish on Contineum Therapeutics stock, sees upside from early-stage trials - Investing.com Canada

Oct 23, 2024
pulisher
Oct 22, 2024

Contineum stock draws bullish view at Baird (CTNM:NASDAQ) - Seeking Alpha

Oct 22, 2024
pulisher
Oct 22, 2024

Contineum Therapeutics (NASDAQ:CTNM) Research Coverage Started at Robert W. Baird - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Baird bullish on Contineum Therapeutics stock, sees upside from early-stage trials By Investing.com - Investing.com South Africa

Oct 22, 2024
pulisher
Oct 21, 2024

WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis - Quantisnow

Oct 21, 2024
pulisher
Oct 17, 2024

EVP Research Swayze Eric converted options into 125 shares and sold $2,031 worth of shares (53 units at $38.31) (SEC Form 4) - Quantisnow

Oct 17, 2024
pulisher
Oct 06, 2024

Objective long/short (CTNM) Report - Stock Traders Daily

Oct 06, 2024
pulisher
Oct 04, 2024

The US IPO Engine Looks Ready to Speed Ahead in Second Quarter - MSN

Oct 04, 2024
pulisher
Oct 04, 2024

Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) largest shareholders are individual investors with 41% ownership, institutions own 28% - Yahoo Finance

Oct 04, 2024
pulisher
Oct 03, 2024

Financial Metrics Exploration: Understanding Contineum Therapeutics Inc. (CTNM) Through Ratios - The Dwinnex

Oct 03, 2024
pulisher
Oct 03, 2024

Squarepoint Ops LLC Invests $2.64 Million in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat

Oct 03, 2024
pulisher
Oct 01, 2024

SEC Form 4 filed by EVP, Chief Human Resourses Ofc Devers Shannon L. - Quantisnow

Oct 01, 2024
pulisher
Oct 01, 2024

New insider Devers Shannon L. claimed ownership of 7,909 shares (SEC Form 3) - Quantisnow

Oct 01, 2024
pulisher
Oct 01, 2024

Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum - Yahoo Finance

Oct 01, 2024
pulisher
Oct 01, 2024

Rhumbline Advisers Makes New Investment in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World

Oct 01, 2024
pulisher
Sep 30, 2024

Contineum Therapeutics (NASDAQ:CTNM) Trading 5% Higher - Defense World

Sep 30, 2024
pulisher
Sep 30, 2024

Perceptive Advisors LLC Purchases Shares of 1,566,668 Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat

Sep 30, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Contineum Therapeutics stock rides wave of promising assets - Investing.com

Sep 27, 2024
pulisher
Sep 26, 2024

Bank of New York Mellon Corp Invests $356,000 in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World

Sep 26, 2024
pulisher
Sep 25, 2024

(CTNM) Investment Analysis and Advice - Stock Traders Daily

Sep 25, 2024
pulisher
Sep 25, 2024

Sandia Investment Management LP Takes $88,000 Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

Contineum Therapeutics, Inc.'s Lock-Up Period Will End on October 2nd (NASDAQ:CTNM) - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

Contineum Therapeutics, Inc.'s Lock-Up Period To End on October 2nd (NASDAQ:CTNM) - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

CD Projekt (OTCMKTS:OTGLY) Shares Up 2.8% - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

Contineum Therapeutics, Inc.’s Lock-Up Period To End on October 2nd (NASDAQ:CTNM) - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

BW LPG (OTCMKTS:BWLLY) Stock Price Down 0.1% - Defense World

Sep 25, 2024
pulisher
Sep 24, 2024

NET Power Inc. (NYSE:NPWR) Major Shareholder Sells $12,348.00 in Stock - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Direxion Daily MSFT Bull 2X Shares Announces Quarterly Dividend of $0.33 (NASDAQ:MSFU) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Hilton Worldwide Holdings Inc. (NYSE:HLT) Shares Acquired by Xponance Inc. - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Blue Star Gold (CVE:BAU) Shares Down 9.1% - Defense World

Sep 24, 2024

Contineum Therapeutics Inc Stock (CTNM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):